# V1 Empirics Check — openai/gpt-5.1-codex-mini (Variant A)

**Model:** openai/gpt-5.1-codex-mini
**Variant:** A
**Date:** 2026-03-27T00:36:41.670464

---

**Idea Fidelity**

The paper is broadly faithful to the manifested idea: it studies the causal effect of state-level legalization of raw milk sales on foodborne illness using panel data from the CDC NORS system and adopts modern DiD methodology. The manuscript does, however, depart from the original vision in key respects. The manifest emphasized “staggered legalization of various raw milk distribution channels: retail, on-farm, herdshare, farmers market” across “30+ states changed laws 2004–2023,” with Callaway–Sant’Anna and Poisson DiD as the intended identification strategy. The paper instead focuses on only 15 states that legalized during 1998–2023, with 24 already treated before the sample begins, and does not exploit channel heterogeneity beyond a brief robustness check. The Callaway–Sant’Anna estimator is applied only to a binary “any outbreak” indicator in a restricted sample, rather than being the main identification tool for the count outcome. The limited number of treated states and the absence of a detailed treatment-timing narrative reduce the paper’s alignment with the manifest’s emphasis on an abundant, staggered DiD setting. Addressing these misalignments—especially by clarifying why only 15 states obey the “staggered adoption” assumption and by more fully leveraging the promised heterogeneous channel variation—would improve fidelity.

---

**Summary**

The paper estimates the causal impact of legalizing raw milk sales on foodborne illness outbreaks using a Poisson TWFE design and a Callaway–Sant’Anna event study. Leveraging NORS data from 1998–2023, the author(s) find that legalization is associated with a statistically insignificant 40 percent increase in unpasteurized-dairy outbreaks—substantially smaller than the cross-sectional odds ratio of 3.87 reported in prior work. Placebo outcomes for pasteurized dairy and non-dairy outbreaks are null, and the event study shows no clear post-treatment effect, suggesting the large cross-sectional correlation primarily reflects selection into legalization.

---

**Essential Points**

1. **Pre-trends undermine the key parallel-trends assumption.**  
   The presented Callaway–Sant’Anna event study (Table 3) shows several pre-treatment ATT estimates that are statistically significant and systematically negative (e.g., event times −6 and −4). If these estimates are reliable, they indicate treated states were already diverging from never-treated states prior to legalization, which directly threatens the credibility of the DiD design. The paper needs to investigate and explain these apparent pre-trends—are they artifacts of extremely low counts, small sample size, or mis-specified reference periods? A more conventional stacked-study event study (with balanced leads/lags) or an analysis of pre-existing trends in raw milk-specific surveillance (possibly via placebo time windows) is needed before the causal interpretation is credible.

2. **Limited treatment variation and treatment definition need clarification.**  
   The manifest suggested “30+ states changed laws,” but the paper’s analysis relies on only 15 states that expanded access during 1998–2023, while 24 states were “always legal” and 12 “never legal.” This raises concerns about limited within-state variation and the representativeness of the treated sample. Moreover, coding treatment as the first year in which *any* sales channel is legalized collapses retail, farm-gate, and herdshare regimes, which differ greatly in practical access. Without showing robustness to alternative definitions (e.g., channel-specific treatment indicators, cumulative exposure or intensity), the interpretation of a single “legal” indicator is unclear. Please justify the trimming to 15 newly legal states, document the timing of each adoption more clearly (e.g., by reporting cluster sizes or adoption cohorts), and, if possible, exploit the richer channel variation promised in the manifest to check whether the estimated effect varies meaningfully by access breadth.

3. **Power and measurement limitations should be acknowledged more transparently.**  
   With just 267 unpasteurized dairy outbreaks over 1,326 state-years and 85% zero cell counts, the analysis is severely underpowered, leading to wide confidence intervals that include both large positive and negative effects. The paper mentions this limitation in passing, but it should be foregrounded when reporting results; the conclusion that legalization “increases the expected outbreak count by 40%” is misleading when the standard error is as large as the point estimate. Additionally, the outcome reflects reported outbreaks and is thus subject to surveillance intensity differences that correlate with legalization. While the non-dairy placebo is informative, it leaves substantial residual concerns—especially given the positive (if imprecise) coefficient on non-dairy outbreaks. A more thorough discussion of statistical power and reporting bias, possibly backed by a sensitivity analysis (e.g., bounding analysis for surveillance improvements), is essential for assessing the reliability of the estimates.

If addressing these points would require substantially new data or re‑analysis, the authors should acknowledge that the paper is not yet ready for publication.

---

**Suggestions**

1. **Strengthen the event study evidence.**  
   - Re-estimate the event study using a stacked DiD framework that includes all leads/lags with sufficient observations, and plot the estimates with confidence intervals. This might help distinguish genuine pre-trends from noisy estimates due to sparse data.  
   - Consider alternative normalization (e.g., using the year before treatment as the omitted category) and report how sensitive the pre-period coefficients are to different choices.  
   - If the negative pre-trends persist, explore potential explanations—are states legalizing after a decline in outbreaks, or are data artifacts (e.g., delayed reporting) driving those patterns? If they reflect real differential trends, the main specification should adjust (e.g., include state-specific trends or using a restricted pre-period).  
   - As a robustness check, supplement the event study with a within-state “lead” placebo test (assigning treatment fictitiously ahead of legalization) to gauge the presence of anticipation effects.

2. **Deepen the treatment heterogeneity analysis.**  
   - Disaggregate treatment indicators by sales channel (retail, farm-gate, herdshare) and estimate separate effects where sample size permits. The manifest’s “heterogeneous effects depending on channel” is an important story that deserves more than a single subsample robustness check.  
   - Explore intensity of treatment by constructing an ordinal “access index” (e.g., 0 = illegal, 1 = herdshare, 2 = farm-gate, 3 = retail) and test for gradient effects. Even with small counts, this can convey whether broader access drives larger changes.  
   - If channel-specific data are too sparse, at least describe more precisely which states fall into each category, the timing of transitions, and whether results differ meaningfully when restricting to non-herdshare reforms.

3. **Address surveillance bias explicitly.**  
   - The positive (though insignificant) coefficient on non-dairy outbreaks suggests legalization might correlate with surveillance investment. The manuscript should explore this further, perhaps by including state-year controls for health department staffing (if available), or by correlating legalization timing with other indicators of public health investment (e.g., CDC funding per capita, number of reported outbreaks per capita across all categories).  
   - Alternatively, report results using an outcome less sensitive to surveillance intensity, such as outbreaks involving hospitalization (which are more likely to be detected regardless of surveillance). You already have hospitalization estimates—these could be discussed more substantively, especially since they show a larger point estimate.  
   - If surveillance bias cannot be ruled out, the conclusion should be more guarded, emphasizing that the null effect could reflect offsetting increases in consumption and improvements in detection.

4. **Improve the paper’s power discussion and framing.**  
   - The conclusion should stress the wide confidence intervals and the fact that the estimate is statistically indistinguishable from both large increases and no effect. A short power calculation (e.g., minimum detectable effect given the panel size and variation) would help readers gauge what the data can and cannot identify.  
   - When comparing to Whitten et al.’s odds ratio of 3.87, clarify that the current estimate is precise enough to reject such a large effect—if it is—or explain why the data lack the power to do so.  
   - Consider reporting standardized effect sizes (e.g., relative to pre-treatment standard deviation) for the main outcome and placebos, so readers can compare magnitudes across specifications.

5. **Clarify data construction and sample composition.**  
   - Provide a table listing the legalization year and channel for each of the 15 newly legalized states, alongside key outcome statistics (average outbreak counts before/after). This would help readers assess treatment timing and the overlap between treated and control states.  
   - Explain why only 15 states changed laws between 1998 and 2023, despite the manifest claiming “30+ states changed laws.” Was the manifest referring to earlier periods, to narrower channels, or to proposed (but not enacted) reforms?  
   - Since 24 states are “always treated,” discuss whether and how they contribute to identification—does the TWFE model effectively compare newly legalizing states to these always-legal states, or only to never-legal ones? If necessary, re-run the main specification excluding always-treated states to isolate the within-state variation more cleanly.

6. **Expand the discussion of policy mechanisms.**  
   - The narrative around the “pasteurization illusion” is compelling but would benefit from more empirical grounding. For example, is there evidence that the dairy-intensive, legalizing states had higher pre-treatment outbreak counts or more raw milk consumption even before legalization?  
   - If data on raw milk consumption or dairy production are unavailable, consider referencing qualitative evidence (e.g., state-level raw milk advocacy activity) to substantiate the selection story.  
   - Elaborate on the implications for policy: given the imprecise estimate, what stance should regulators take? Should they focus on surveillance and education rather than outright bans? Clearer policy takeaways would strengthen the paper’s impact.

Overall, the paper tackles an interesting and timely question and makes a good start at applying causal methods to raw milk regulation. Addressing the above points would substantially improve the credibility and interpretability of the results.
